Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia.

Kjær M, Geisen C, Akkök ÇA, Wikman A, Sachs U, Bussel JB, Nielsen K, Walles K, Curtis BR, Vidarsson G, Järås K, Skogen B.

Transfus Apher Sci. 2019 Dec 31:102712. doi: 10.1016/j.transci.2019.102712. [Epub ahead of print] Review.

2.

Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).

Lee EJ, Izak M, Bussel JB.

Br J Haematol. 2020 Jan 3. doi: 10.1111/bjh.16328. [Epub ahead of print]

PMID:
31900937
3.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ.

Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.

4.

Identifying and Treating Refractory ITP: Difficulty in Diagnosis and Role of Combination Treatment.

Miltiadous O, Hou M, Bussel JB.

Blood. 2019 Nov 22. pii: blood.2019003599. doi: 10.1182/blood.2019003599. [Epub ahead of print]

PMID:
31756253
5.

Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.

Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, Zehnder JL.

Haematologica. 2019 Jul 11. pii: haematol.2019.226688. doi: 10.3324/haematol.2019.226688. [Epub ahead of print]

6.

Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.

Garabet L, Ghanima W, Hellum M, Sandset PM, Bussel JB, Tran H, Henriksson CE.

Platelets. 2019 Jul 7:1-7. doi: 10.1080/09537104.2019.1639655. [Epub ahead of print]

PMID:
31280643
7.

Thrombopoietin receptor agonists: ten years later.

Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB.

Haematologica. 2019 Jun;104(6):1112-1123. doi: 10.3324/haematol.2018.212845. Epub 2019 May 9. Review.

8.

Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia.

Jin JC, Lakkaraja MM, Ferd P, Manotas K, Gabor J, Wissert M, Berkowitz RL, McFarland JG, Bussel JB.

Am J Hematol. 2019 Aug;94(8):E213-E215. doi: 10.1002/ajh.25503. Epub 2019 May 16. No abstract available.

PMID:
31056760
9.

Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia.

Hogan M, Geyer JT, Bussel JB.

Am J Hematol. 2019 Jul;94(7):E196-E198. doi: 10.1002/ajh.25496. Epub 2019 May 3. No abstract available.

PMID:
31012979
10.

Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM.

Am J Hematol. 2019 Jul;94(7):741-750. doi: 10.1002/ajh.25479. Epub 2019 Apr 29.

PMID:
30945320
11.

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.

Garabet L, Ghanima W, Rangberg A, Teruel-Montoya R, Martinez C, Lozano ML, Nystrand CF, Bussel JB, Sandset PM, Jonassen CM.

Platelets. 2020;31(2):198-205. doi: 10.1080/09537104.2019.1585527. Epub 2019 Mar 18.

PMID:
30885035
12.

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.

Haematologica. 2019 Nov;104(11):2283-2291. doi: 10.3324/haematol.2018.202283. Epub 2019 Mar 7.

13.

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.

Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM.

Am J Hematol. 2019 May;94(5):546-553. doi: 10.1002/ajh.25444. Epub 2019 Mar 13.

14.

Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB.

Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27.

PMID:
30592022
15.

Health-related quality of life in adult primary immune thrombocytopenia.

Sestøl HG, Trangbæk SM, Bussel JB, Frederiksen H.

Expert Rev Hematol. 2018 Dec;11(12):975-985. doi: 10.1080/17474086.2018.1548930. Epub 2018 Nov 27. Review.

PMID:
30444433
16.

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29.

17.

Integrating Healthy Eating into Evidence-Based Home Visiting Models: An Analysis of Programs and Opportunities for Dietetic Practice.

Welker EB, Lott MM, Sundermann JL, Bussel JB, Story MT.

J Acad Nutr Diet. 2019 Sep;119(9):1423-1436. doi: 10.1016/j.jand.2018.08.167. Epub 2018 Nov 8. No abstract available.

PMID:
30415895
18.

Avatrombopag.

Bussel JB.

Br J Haematol. 2018 Nov;183(3):342-343. doi: 10.1111/bjh.15568. Epub 2018 Oct 23. No abstract available.

PMID:
30351482
19.

Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaas9563. doi: 10.1126/scitranslmed.aas9563.

PMID:
30209246
20.

IVIg and FcγRIIb in kids with ITP: individualizing therapy.

Despotovic JM, Bussel JB.

Blood. 2018 Aug 30;132(9):877-878. doi: 10.1182/blood-2018-07-861690. No abstract available.

PMID:
30166359
21.

Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.

Guitton Z, Terriou L, Lega JC, Nove-Josserand R, Hie M, Amoura Z, Bussel JB, Hamidou M, Rosenthal E, Lioger B, Chauveau D, Chaminade A, Magy-Bertrand N, Michel M, Audia S, Godeau B, Mahevas M.

Rheumatology (Oxford). 2018 Aug 1;57(8):1432-1438. doi: 10.1093/rheumatology/key119.

PMID:
29757439
22.

Screening for Wiskott-Aldrich syndrome by flow cytometry.

Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA.

J Allergy Clin Immunol. 2018 Jul;142(1):333-335.e8. doi: 10.1016/j.jaci.2018.04.017. Epub 2018 May 3. No abstract available.

PMID:
29729304
23.

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

Fassel H, Bussel JB, Roberts SS, Modak S.

J Pediatr Hematol Oncol. 2019 May;41(4):e257-e259. doi: 10.1097/MPH.0000000000001187.

PMID:
29683946
24.

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP.

Am J Hematol. 2018 Jul;93(7):882-888. doi: 10.1002/ajh.25110. Epub 2018 May 6.

25.

Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.

Ghanima W, Boiocchi L, Lee CS, Feng X, Geyer JT, Gudbrandsdottir S, Orazi A, Junker P, Bussel JB.

Platelets. 2019;30(2):222-228. doi: 10.1080/09537104.2017.1411586. Epub 2018 Jan 2.

PMID:
29293383
26.

Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.

Garabet L, Ghanima W, Monceyron Jonassen C, Skov V, Holst R, Mowinckel MC, C Hasselbalch H, A Kruse T, Thomassen M, Liebman H, Bussel JB, Sandset PM.

Platelets. 2019;30(2):206-212. doi: 10.1080/09537104.2017.1394451. Epub 2017 Dec 7.

PMID:
29215956
27.
28.

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.

Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB.

Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Erratum in: Blood. 2018 Feb 8;131(6):709.

PMID:
29042367
29.

Fostamatinib for persistent/chronic adult immune thrombocytopenia.

Newland A, Lee EJ, McDonald V, Bussel JB.

Immunotherapy. 2018 Jan;10(1):9-25. doi: 10.2217/imt-2017-0097. Epub 2017 Oct 2. Review.

30.

TPO for ITP in pregnancy.

Bussel JB, Lee EJ.

Blood. 2017 Aug 31;130(9):1073-1074. doi: 10.1182/blood-2017-07-793356. No abstract available.

PMID:
28860321
31.

Imaging and management of fetuses and neonates with alloimmune thrombocytopenia.

Kovanlikaya A, Tiwari P, Bussel JB.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26690. Epub 2017 Jul 4. Review.

PMID:
28675682
32.

Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.

Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL.

Am J Hematol. 2017 Aug;92(8):730-738. doi: 10.1002/ajh.24759. Epub 2017 Apr 26.

33.

Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases.

Tsang HC, Bussel JB, Mathew S, Liu YC, Imahiyerobo AA, Orazi A, Geyer JT.

Mod Pathol. 2017 Apr;30(4):486-498. doi: 10.1038/modpathol.2016.218. Epub 2017 Jan 6.

34.

Immune thrombocytopenia: a need for assisted suicide.

Bussel JB, Cooper N.

Br J Haematol. 2017 Jan;176(2):154. doi: 10.1111/bjh.14435. Epub 2016 Nov 23. No abstract available.

PMID:
27879988
35.

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM.

Haematologica. 2016 Nov;101(11):1327-1332. Epub 2016 Aug 11.

36.

Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.

Lakkaraja M, Jin JC, Manotas KC, Vinograd CA, Ferd P, Gabor J, Wissert M, Berkowitz RL, McFarland JG, Bussel JB.

Transfusion. 2016 Oct;56(10):2449-2454. doi: 10.1111/trf.13779. Epub 2016 Sep 9.

PMID:
27611703
37.

Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.

Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB.

Am J Hematol. 2016 Sep;91(9):907-11. doi: 10.1002/ajh.24434. Epub 2016 Jun 20.

38.

Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia.

Lakkaraja M, Berkowitz RL, Vinograd CA, Manotas KC, Jin JC, Ferd P, Gabor J, Wissert M, McFarland JG, Bussel JB.

Am J Obstet Gynecol. 2016 Oct;215(4):471.e1-9. doi: 10.1016/j.ajog.2016.04.033. Epub 2016 Apr 27.

PMID:
27131591
39.

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.

Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18.

PMID:
27103127
40.

Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Kucine N, Viny AD, Rampal R, Berger M, Socci N, Viale A, Bussel JB, Levine RL, Rapaport F.

Haematologica. 2016 Jun;101(6):e237-9. doi: 10.3324/haematol.2016.142935. Epub 2016 Mar 18. No abstract available.

41.

What do we know about intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia?

Bussel JB.

Transfusion. 2016 Jan;56(1):17-8. doi: 10.1111/trf.13412. No abstract available.

PMID:
26756707
42.

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.

Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.

Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum in: Lancet Haematol. 2015 Oct;2(10):e407.

PMID:
26688484
43.

Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.

Bussel JB, Wang X, Lopez A, Eisen M.

Hematology. 2016 May;21(4):257-62. doi: 10.1179/1607845415Y.0000000041. Epub 2015 Aug 7.

PMID:
26251926
44.

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.

Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28. Erratum in: Lancet. 2015 Oct 24;386(10004):1630.

PMID:
26231455
45.

Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.

Gerrits AJ, Leven EA, Frelinger AL 3rd, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB.

Blood. 2015 Sep 10;126(11):1367-78. doi: 10.1182/blood-2014-09-602573. Epub 2015 Jul 29.

46.

Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies.

Liu ZJ, Bussel JB, Lakkaraja M, Ferrer-Marin F, Ghevaert C, Feldman HA, McFarland JG, Chavda C, Sola-Visner M.

Blood. 2015 Sep 3;126(10):1234-6. doi: 10.1182/blood-2014-11-611020. Epub 2015 Jul 24.

47.

Collaborating to support Healthy Kids, Healthy Communities partnerships.

Strunk SL, Brennan LK, Bors PA, Bussel JB, Eng E, Leonard BA.

J Public Health Manag Pract. 2015 May-Jun;21 Suppl 3:S8-15. doi: 10.1097/PHH.0000000000000187.

PMID:
25828227
48.

The Healthy Kids, Healthy Communities national program.

Strunk SL, Bussel JB.

J Public Health Manag Pract. 2015 May-Jun;21 Suppl 3:S1-3. doi: 10.1097/PHH.0000000000000188.

PMID:
25828210
49.

Review of fetal and neonatal immune cytopenias.

Lewin S, Bussel JB.

Clin Adv Hematol Oncol. 2015 Jan;13(1):35-43. Review.

PMID:
25679972
50.

Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).

Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.

Pediatr Blood Cancer. 2015 Feb;62(2):208-213. doi: 10.1002/pbc.25136. Epub 2014 Oct 24.

Supplemental Content

Loading ...
Support Center